Format

Send to

Choose Destination
  • Showing results for locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment. Your search for Locoregional recurence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment retrieved no results.
Cancer Res Treat. 2016 Oct;48(4):1363-1372. Epub 2016 Feb 18.

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.

Author information

1
Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
2
Department of Radiation Oncology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
3
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
4
Department of Radiation Oncology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

Abstract

PURPOSE:

The purpose of this study is to determine whether breast cancer subtype can affect locoregional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) after neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT).

MATERIALS AND METHODS:

We evaluated 335 consecutive patients with clinical stage II-III breast cancer who received NAC plus BCT from 2002 to 2009. Patients were classified according to six molecular subtypes: luminal A (hormone receptor [HR]+/HER2-/Ki-67 < 15%, n=113), luminal B1 (HR+/HER2-/Ki-67 ≥ 15%, n=33), luminal B2 (HR+/HER2+, n=83), HER2 with trastuzumab (HER2[T+]) (HR-/HER2+/use of trastuzumab, n=14), HER2 without trastuzumab (HER2[T-]) (HR-/HER2+, n=31), and triple negative (TN) (HR-/HER2-, n=61).

RESULTS:

After a median follow-up period of 7.2 years, 26 IBTRs and 37 LRRs occurred. The 5-year LRR-free survival rates were luminal A, 96.4%; B1, 93.9%; B2, 90.3%; HER2(T+), 92.9%; HER2(T-), 78.3%; and TN, 79.6%. The 5-year IBTR-free survival rates were luminal A, 97.2%; B1, 93.9%; B2, 92.8%; HER2(T+), 92.9%; HER2(T-), 89.1%; and TN, 84.6%. In multivariate analysis, HER2(T-) (IBTR: hazard ratio, 4.2; p=0.04 and LRR: hazard ratio, 7.6; p < 0.01) and TN subtypes (IBTR: hazard ratio, 6.9; p=0.01 and LRR: hazard ratio, 8.1; p < 0.01) were associated with higher IBTR and LRR rates. A pathologic complete response (pCR) was found to show correlation with better LRR and a tendency toward improved IBTR controls in TN patients (IBTR, p=0.07; LRR, p=0.03).

CONCLUSION:

The TN and HER2(T-) subtypes predict higher rates of IBTR and LRR after NAC and BCT. A pCR is predictive of improved IBTR or LRR in TN subtype.

KEYWORDS:

Breast neoplasms; Ipsilateral breast tumor recurrence; Local neoplasm recurrence; Molecular subtype; Neoadjuvant chemotherapy

PMID:
26910473
PMCID:
PMC5080807
DOI:
10.4143/crt.2015.456
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center